

A double blind, randomised, placebo controlled parallel group study of cannabis based medicine extract (CBME), in the treatment of peripheral neuropathic pain characterised by allodynia

Submission date 14/11/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 18/11/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 26/09/2019	Condition category Signs and Symptoms	<input type="checkbox"/> Individual participant data

Plain English Summary

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Stephen Wright

Contact details

GW Pharma Ltd
Porton Down Science Park
Salisbury
United Kingdom
SP4 0JQ

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00711880

Secondary identifying numbers

Study information

Scientific Title

A double blind, randomised, placebo controlled parallel group study of cannabis based medicine extract (CBME), in the treatment of peripheral neuropathic pain characterised by allodynia

Acronym

GWNP0101

Study hypothesis

Tetrahydrocannabinol (THC):cannabidiol (CBD), 1:1 relieves peripheral neuropathic pain characterised by allodynia.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Study design

Double-blind randomised placebo-controlled parallel-group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Condition

Peripheral neuropathic pain, characterised by allodynia

Interventions

THC:CBD, 1:1 and placebo

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Tetrahydrocannabinol (THC), cannabidiol (CBD)

Primary outcome measure

Efficacy in relieving peripheral neuropathic pain after 5 weeks of treatment

Secondary outcome measures

1. Qualitative aspects of pain as reported the Neuropathic Pain Scale (NPS)
2. The physical and psychological effects of pain using measures of sleep disturbance, the Pain Disability Index (PDI) and General Health Questionnaire (GHQ-12)
3. Patients cognitive function using the Brief Repeatable Battery of Neuropsychological tests (BRB-N)
4. Patient perception of change in allodynia and pain on movement after 5 weeks of treatment
5. Tolerability of CBME using the adverse event profile, electrocardiogram (ECG), clinical laboratory tests and vital signs

Overall study start date

13/05/2002

Overall study end date

03/03/2004

Eligibility

Participant inclusion criteria

1. Patient or legal representative is willing and able to give informed consent for participation in the study (if the patient is unable to read or to sign the document, consent procedures as detailed in the Declaration of Helsinki must be followed)
2. Male or Female, aged 18 years or above
3. Chronic peripheral neuropathic pain of at least 6 months duration
4. Presence of mechanical allodynia within the territory of the affected nerve(s)
5. Evidence of sensory change in the affected nerve by simple clinical tests
6. Pain with a severity score of 4 or more on at least 4 completed BS-11 scores in the baseline week
7. Stable dose of current analgesic medication for at least 2 weeks prior to study entry
8. Female patients of child bearing potential and male patients whose partner is of child bearing potential are willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter
9. Willing for his or her names to be notified to the Home Office for participation in this study
10. Willing to allow his or her General Practitioner and Consultant, if appropriate, to be notified of participation in the study
11. No cannabinoid use (cannabis, Marinolâ or Nabilone) at least 7 days before Visit 1 and willing to abstain from any use of cannabis during the study
12. Able (in the Investigators opinion), and willing to comply with all study requirements

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

80

Total final enrolment

145

Participant exclusion criteria

1. History of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition
2. Concomitant severe non-neuropathic pain or the presence of cancer related neuropathic pain or neuropathic pain resulting from diabetes mellitus
3. Known history of alcohol or substance abuse
4. Severe cardiovascular disorder, such as ischaemic heart disease, arrhythmias (other than well controlled atrial fibrillation), poorly controlled hypertension or severe heart failure
5. History of epilepsy
6. Female patient who is pregnant, lactating or planning pregnancy during the course of the study
7. Male patient who is currently receiving and unwilling to stop sildenafil (Viagra®) and unwilling to stop for the duration of the study
8. Regular levodopa therapy within 7 days of study entry
9. Significant renal or hepatic impairment
10. Known or suspected hypersensitivity to cannabinoids
11. Scheduled elective surgery or other procedures requiring general anaesthesia during the study
12. Terminal illness
13. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or may influence the result of the study, or the patients ability to participate in the study
14. Travel outside the UK planned during the study
15. Donation of blood during the study
16. Patients who have participated in another research study in the past 12 weeks
17. Patients previously randomised into this study

Recruitment start date

13/05/2002

Recruitment end date

03/03/2004

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

GW Pharma Ltd

Salisbury

United Kingdom

SP4 0JQ

Sponsor information

Organisation

GW Pharma Ltd (UK)

Sponsor details

Porton Down Science Park

Salisbury

United Kingdom

SP4 0JQ

Sponsor type

Industry

ROR

<https://ror.org/01gtctx88>

Funder(s)

Funder type

Industry

Funder Name

GW Pharma Ltd (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results			26/09/2019	No	No
Results article	results	15/12/2007	26/09/2019	Yes	No